3 documents

Read All
22:56 , Jan 25, 2019 |  BioCentury  |  Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
Read More
00:37 , Jan 25, 2019 |  BC Week In Review  |  Financial News

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million on Jan. 23 in a series B round on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor,...
Read More
14:54 , Jan 23, 2019 |  BC Extra  |  Financial News

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million in a series B round Wednesday on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor, ATN-249, to...
Read More